iShares Biotechnology ETF
277 hedge funds and large institutions have $3.24B invested in iShares Biotechnology ETF in 2013 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 88 increasing their positions, 94 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
6% less repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 94
60% less call options, than puts
Call options by funds: $177M | Put options by funds: $443M
Holders
277
Holding in Top 10
19
Calls
$177M
Puts
$443M
Top Buyers
| 1 | +$204M | |
| 2 | +$172M | |
| 3 | +$73.3M | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$52.5M |
| 5 |
Canada Life
Winnipeg,
Manitoba, Canada
|
+$23.8M |
Top Sellers
| 1 | -$115M | |
| 2 | -$50.4M | |
| 3 | -$33.3M | |
| 4 |
Barclays
London,
United Kingdom
|
-$18.2M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$10.2M |